Table 4 Estimated pharmacodynamic parameters after fitting the radiation and radiosensitizing model to the data of studies 1, 2, and 3
From: Model-based assessment of combination therapies – ranking of radiosensitizing agents in oncology
Parameter | Population Median (RSE%) | Between-subject variabilitya (RSE%) | Description |
|---|---|---|---|
\({k}_{g}\)[1/day] | 0.44 (1.3) | - | Natural growth rate |
\({k}_{k}\)[1/day] | 0.3 (1.7) | - | Natural kill rate |
\(\alpha\)[1/Gy] | 0.06 (7) | 50 (25) | Linear radiation parameter |
\({\gamma }_{1}, {\gamma }_{2}, {\gamma }_{3}\)[1/Gy] | 0.027 (11), 0.044 (20), 0.02 (15) | 64 (34) | Growth rate inhibition parameter |
\({V}_{\mathrm{0,1}}, {V}_{\mathrm{0,2}}, {V}_{\mathrm{0,3}}\)[mm3] | 26 (4.3), 44 (4.4), 22 (5) | 40 (18) | Initial volume of proliferating cells |
\({a}_{Rs1}\)[\(\mathrm{mL}/\mathrm{\mu g}\)] | 0.65 (13) | - | Stimulation of short-term effect |
\({a}_{Rs2}\)[\(\mathrm{mL}/\mathrm{\mu g}\)] | 0.2 (30) | - | |
\({a}_{Rs3}\)[\(\mathrm{mL}/\mathrm{\mu g}\)] | 0.14 (32) | - | |
\({b}_{Rs1}\)[\(\mathrm{mL}/\mathrm{\mu g}\)] | 0.26 (31) | - | Stimulation of long-term effect |
\({b}_{Rs2}\)[\(\mathrm{mL}/\mathrm{\mu g}\)] | 0.4 (34) | - | |
\({b}_{Rs3}\)[\(\mathrm{mL}/\mathrm{\mu g}\)] | 0.16 (40) | - | |
\({\sigma }_{prop}\)[%] | 0.35 (2.2) | - | Proportional error |
\({\sigma }_{add}\)[mm3] | 4.4 (7.3) | - | Additive error |